Countering Coupons: Large Employers Will Boost Copay Accumulator Programs In 2021
Executive Summary
Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.
You may also be interested in...
Presidential Arm Twisting: Drug Pricing Order Would Advance International Benchmarks Unless Industry Offers Alternative
Industry has 30 days to come up with a better idea that would “end foreign free riding” and close the gap between drug prices in the US and abroad, President Trump says. Administration also wants to revive rebate reform.
Medicaid Value-Based Payment Proposal Stops Short Of ‘Portability’ Solutions
US Congress may need to weigh in on how installment payments would be handled if patients switch from Medicaid to commercial insurance or from one state Medicaid plan to another, congressional staffer suggests.
Employers Would ‘Welcome’ Government Role In Covering High-Cost Therapies
Annual large employer health benefits survey for 2020 and beyond finds support for government price negotiation and payment through a national fund. Plans to expand point-of-sale rebates and coupon accumulator programs also reported.